BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
Autor: | Byung-Ho Nam, Jeong Eon Lee, Jong Won Lee, Gyungyub Gong, Peter D Beitsch, Sei Hyun Ahn, Jinil Han, Mi Jeong Kwon, Seok Jin Nam, Sae Byul Lee, Young Kee Shin |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Adjuvant Chemotherapy Physiology Receptor ErbB-2 medicine.medical_treatment Cancer Treatment lcsh:Medicine Kaplan-Meier Estimate Biochemistry Metastasis 0302 clinical medicine Risk Factors Breast Tumors Medicine and Health Sciences lcsh:Science Aged 80 and over Multidisciplinary Pharmaceutics Hazard ratio Hormonal Therapy Middle Aged Prognosis Body Fluids Bioassays and Physiological Analysis Receptors Estrogen Hormone receptor Chemotherapy Adjuvant 030220 oncology & carcinogenesis Lymphatic Metastasis Hormone Bioassays Hormonal therapy Female Lymph Anatomy Receptors Progesterone Research Article Clinical Oncology Adult medicine.medical_specialty Breast Neoplasms Research and Analysis Methods Disease-Free Survival 03 medical and health sciences Cancer Chemotherapy Breast cancer Drug Therapy Asian People Internal medicine Breast Cancer Republic of Korea medicine Chemotherapy Humans Aged Proportional Hazards Models business.industry Proportional hazards model lcsh:R Cancers and Neoplasms Biology and Life Sciences medicine.disease Hormones 030104 developmental biology lcsh:Q Hormone therapy Clinical Medicine business Biochemical Analysis |
Zdroj: | PLoS ONE PLoS ONE, Vol 13, Iss 11, p e0207155 (2018) |
ISSN: | 1932-6203 |
Popis: | The Breast Cancer Test (BCT) score has been validated for its ability to predict the risk of distant metastasis in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. This study aimed to examine the value of the BCT score for predicting the benefit of adjuvant chemotherapy for Korean women with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. The study included 346 patients treated with either hormone therapy alone (n = 203) or hormone therapy plus chemotherapy (n = 143), and compared patient survival between the two treatment groups. The effect of BCT score on patient survival by treatment group was assessed using Cox proportional hazards models. Based on the results, the BCT score was prognostic for distant metastasis-free survival and breast cancer-specific survival in the hormone therapy alone group. There was no significant difference between the treatment groups in terms of 10-year distant metastasis-free survival in the overall patient population. However, when patients were classified as low risk (n = 266) and high risk (n = 80) according to the BCT score, addition of adjuvant chemotherapy to hormone therapy for patients classified as BCT high-risk group led to a significant improvement in 10-year distant metastasis-free survival, from 65.4% to 91.9% (hazard ratio, 0.18; 95% confidence interval, 0.05-0.64; P = 0.003); in contrast, there was no benefit for the BCT low-risk group. The stratification of patients according to the BCT score also identified clinically high-risk patients who may not benefit from chemotherapy. Results were similar for breast cancer-specific survival. In conclusion, the BCT score was not only of prognostic value but was also a predictor of chemotherapy benefit for Korean patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |